Combination Antifungal Therapy for Invasive Mucormycosis in Immunocompromised Hosts: A Single-Center Experience
Resource type
Journal Article
Authors/contributors
- Lu, Brian (Author)
- Ha, David (Author)
- Shen, Sa (Author)
- Ferguson Toll, Jessica (Author)
- Kim, Ailin (Author)
- Kim, Sarah (Author)
- Mui, Emily (Author)
- Deresinski, Stan (Author)
- Holubar, Marisa (Author)
- Alegria, William (Author)
Title
Combination Antifungal Therapy for Invasive Mucormycosis in Immunocompromised Hosts: A Single-Center Experience
Abstract
Abstract
Combination antifungal therapy for invasive mucormycosis remains controversial and is inconsistently defined in prior studies. In a cohort of immunocompromised patients with invasive mucormycosis, we found no difference in 6-week mortality with upfront nor salvage combination therapy compared to monotherapy.
Publication
Open Forum Infectious Diseases
Pages
ofae103
Date
2024-02-22
Language
en
ISSN
2328-8957
Short Title
Combination Antifungal Therapy for Invasive Mucormycosis in Immunocompromised Hosts
Accessed
3/10/24, 5:18 PM
Library Catalog
DOI.org (Crossref)
Citation
Lu, B., Ha, D., Shen, S., Ferguson Toll, J., Kim, A., Kim, S., Mui, E., Deresinski, S., Holubar, M., & Alegria, W. (2024). Combination Antifungal Therapy for Invasive Mucormycosis in Immunocompromised Hosts: A Single-Center Experience. Open Forum Infectious Diseases, ofae103. https://doi.org/10.1093/ofid/ofae103
ORGANISMS
Link to this record